Literature DB >> 25614854

Focal treatment for genetic disorders (a fairy tale or a true story?).

Mohamad Hossein Nikoo1, Mohamad Vahid Jorat1, Amir Aslani1.   

Abstract

Entities:  

Keywords:  Ablation; Arrhythmia; Genetic Disorder

Year:  2014        PMID: 25614854      PMCID: PMC4302498     

Source DB:  PubMed          Journal:  Int Cardiovasc Res J        ISSN: 2251-9130


× No keyword cloud information.
Genetic is widely involved in pathophysiology of many diseases. However, certain gene abnormalities could cause cardiac disorders called monogenic disorders (1). Since the genetic information and hence abnormal gene is present in all cells, treatments are focused on symptoms. Nowadays, gene transfer is an uprising option (2). Although all cells carry a mutant gene, the major effect of the disease is localized to a group of cells in some patients. Brugada syndrome results from a sodium channel mutation that causes ST elevation in right precordial leads and may lead to sudden ventricular fibrillation, especially in young males (3). This main electrocardiographic disturbance originates from RV epicardium (4). Therefore, some interventionists try to treat the disease by ablation of this area (5). Although implanting a defibrillator is yet the standard recommendation, it does not cure the disease (6). Thus, ablation of a small area of epicardium which offers a definitive cure also seems appealing. Another example of applying this treatment for a genetic disorder is in catecholaminergic polymorphic ventricular tachycardia (7). This syndrome is caused by a mutation in ryanodine receptor and manifests as polymorphic ventricular tachycardia during exercise or emotion in young adults (8). One study showed that ablation of Premature Ventricular Contraction (PVC) completely treated a patient (7). Although myocardial contraction duration is prolonged in all segments (9) in the patients with long QT syndrome, there is a segment with most prolonged duration in any patient (10). Ablation of PVC on this segment may cure the Ventricular Fibrillation (VF) in this syndrome and prevent sudden cardiac death (11). Another lethal and seemingly incurable syndrome of sudden cardiac death is idiopathic VF. As sounded from nomenclature, the pathophysiology is somewhat unclear and, consequently, the treatment is difficult and only limited to secondary prevention (12). However, ablation of PVC starting the VF looks effective and possible (11). Another recently noticed disease of sudden cardiac disease is early repolarization, especially if it is localized to the inferolateral area (13). Michel Haïssaguerre has described few cases of ablation for this syndrome (14). In conclusion, genetic problems play a significant role in cardiac diseases. They have a widespread nature and present in all body cells; hence, their handling is quite difficult. Palliation therapy and genetic engineering have led to some improvement in management. Yet, many shortages are still present. Of course, simple solutions might be uprising for these hereditary diseases. The clues of this local approach can be found in the case reports mentioned in this article. Of course, more studies and trials are required to be conducted on this approach.
  13 in total

1.  Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation.

Authors:  Takashi Kaneshiro; Yoshihisa Naruse; Akihiko Nogami; Hiroshi Tada; Kentaro Yoshida; Yukio Sekiguchi; Nobuyuki Murakoshi; Yoshiaki Kato; Hitoshi Horigome; Mihoko Kawamura; Minoru Horie; Kazutaka Aonuma
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-02

2.  Idiopathic ventricular fibrillation "Le Syndrome d'Haïssaguerre" and the fear of J waves.

Authors:  Sami Viskin
Journal:  J Am Coll Cardiol       Date:  2009-02-17       Impact factor: 24.094

Review 3.  Early repolarization syndrome – a new electrical disorder associated with sudden cardiac death –.

Authors:  Shinsuke Miyazaki; Ashok J Shah; Michel Haïssaguerre
Journal:  Circ J       Date:  2010-09-11       Impact factor: 2.993

4.  Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.

Authors:  Hitoshi Uchinoumi; Masafumi Yano; Takeshi Suetomi; Makoto Ono; Xiaojuan Xu; Hiroki Tateishi; Tetsuro Oda; Shinichi Okuda; Masahiro Doi; Shigeki Kobayashi; Takeshi Yamamoto; Yasuhiro Ikeda; Tomoko Ohkusa; Noriaki Ikemoto; Masunori Matsuzaki
Journal:  Circ Res       Date:  2010-03-11       Impact factor: 17.367

5.  Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium.

Authors:  Koonlawee Nademanee; Gumpanart Veerakul; Pakorn Chandanamattha; Lertlak Chaothawee; Aekarach Ariyachaipanich; Kriengkrai Jirasirirojanakorn; Khanchit Likittanasombat; Kiertijai Bhuripanyo; Tachapong Ngarmukos
Journal:  Circulation       Date:  2011-03-14       Impact factor: 29.690

6.  Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation.

Authors:  G X Yan; C Antzelevitch
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

7.  Genetic testing for inherited heart disease.

Authors:  Allison L Cirino; Carolyn Y Ho
Journal:  Circulation       Date:  2013-07-02       Impact factor: 29.690

Review 8.  Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.

Authors:  Carol Ann Remme
Journal:  J Physiol       Date:  2013-07-01       Impact factor: 5.182

9.  Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome.

Authors:  Kristina Hermann Haugaa; Thor Edvardsen; Trond P Leren; Jon Michael Gran; Otto A Smiseth; Jan P Amlie
Journal:  Eur Heart J       Date:  2008-10-21       Impact factor: 29.983

Review 10.  Gene therapy to treat cardiovascular disease.

Authors:  Julie A Wolfram; J Kevin Donahue
Journal:  J Am Heart Assoc       Date:  2013-08-20       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.